CDT Equity (CDT) Research & Development (2022 - 2026)
CDT Equity's (CDT) quarterly Research & Development came in at $778000.0 in Q1 2026, down 15.07% YoY from $916000.0 in Q1 2025, and down 53.3% on a QoQ basis from $1.7 million in Q4 2025.
CDT Equity (CDT) Research & Development (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 4 years of Research & Development data on file, last reported at $778000.0 in Q1 2026.
- Quarterly Research & Development fell 15.07% year-over-year to $778000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (up 22.54% YoY) and the FY2025 annual result came in at $5.1 million, up 49.62% from the prior year.
- Research & Development declined to $778000.0 in Q1 2026, from $1.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $3.1 million in Q3 2024 to a low of -$1000.0 in Q4 2022.
- A 4-year average of $857818.2 and a median of $778000.0 in 2026 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 6452.0% in 2025, down 66.93% in 2025.
- Tracing CDT's Research & Development over 4 years: stood at -$1000.0 in 2022, then surged by 13300.0% to $132000.0 in 2024, then surged by 1162.12% to $1.7 million in 2025, then sank by 53.3% to $778000.0 in 2026.
- The last three Research & Development figures came in at $778000.0 (Q1 2026), $1.7 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 97.90 Mn |
| 10 | CDT Equity | 1.64 Mn | 1.64 Mn | - | 302,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 302,000.00 |
| Mar 31, 2026 | 778,000.00 |
| Dec 31, 2025 | 1.67 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Mar 31, 2025 | 916,000.00 |
| Dec 31, 2024 | 132,000.00 |
| Sep 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | 25,000.00 |
| Mar 31, 2024 | 128,000.00 |
| Dec 31, 2022 | -1,000.00 |
| Sep 30, 2022 | 38,000.00 |